In light of recent progress towards clinically-relevant Src inhibitors (reviewed in [31], [58]) and increasing effort devoted to identifying and characterizing inhibitors of PRL-3 (reviewed in [2]), our work offers new insights into the development and clinical application of molecularly targeted cancer therapeutics. The gene discussed is SRC; the disease is cancer.